Pacer Advisors
ACAD icon

Pacer Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Pacer Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47K Buy
+1,841
New +$40.5K ﹤0.01% 2054
2025
Q2 		– Sell
-16,224
Closed -$269K – 3408
2025
Q1 		$269K Buy
+16,224
New +$295K ﹤0.01% 1676
2024
Q3 		– Sell
-1,735
Closed -$28.2K – 2554
2024
Q2 		$28.2K Sell
1,735
-87
-5% -$1.4K ﹤0.01% 3359
2024
Q1 		$33.7K Buy
+1,822
New +$45.1K ﹤0.01% 3325
2021
Q2 		– Sell
-2,882
Closed -$74K – 1396
2021
Q1 		$74K Buy
2,882
+298
+12% +$13.1K ﹤0.01% 1348
2020
Q4 		$138K Buy
2,584
+294
+13% +$14.6K ﹤0.01% 1300
2020
Q3 		$94K Buy
+2,290
New +$98.9K ﹤0.01% 1256
2018
Q4 		– Sell
-17,604
Closed -$365K – 532
2018
Q3 		$365K Buy
+17,604
New +$277K 0.01% 920
2018
Q1 		– Sell
-2,932
Closed -$88K – 1038
2017
Q4 		$88K Sell
2,932
-14,996
-84% -$480K 0.01% 968
2017
Q3 		$675K Buy
17,928
+2,618
+17% +$85.2K 0.06% 496
2017
Q2 		$427K Buy
15,310
+1,636
+12% +$48.8K 0.04% 699
2017
Q1 		$470K Buy
13,674
+2,480
+22% +$87.5K 0.06% 513
2016
Q4 		$323K Buy
11,194
+498
+5% +$13.2K 0.05% 648
2016
Q3 		$340K Buy
+10,696
New +$363K 0.05% 535

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Pacer Advisors's ACAD Position: Q2 2026 in Review

Pacer Advisors opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 1,841 shares worth $47K. The stake represents ﹤0.01% of the portfolio and ranks #2054 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in ACAD as recently as Q1 2025.

Pacer Advisors first reported a position in ACAD in Q3 2016 and has held it in 14 quarters since. The position peaked at $675K in Q3 2017. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Pacer Advisors held 1,841 shares of Acadia Pharmaceuticals worth $47K as of Q2 2026.
  • Acadia Pharmaceuticals was a new Pacer Advisors position in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2054 holding.
  • Pacer Advisors first reported a position in Acadia Pharmaceuticals in Q3 2016 and has held it in 14 quarters since.
  • Pacer Advisors's Acadia Pharmaceuticals position peaked at $675K in Q3 2017.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.